

Short Communication

Actinobacillus pleuropneumoniae serovar 8 predominates in England and Wales

Y. Li, J. T. Bossé, S. M. Williamson, D. J. Maskell, A. W. Tucker, B. W. Wren, A. N. Rycroft, P. R. Langford, BRADP1T Consortium

Actinobacillus pleuropneumoniae is a major cause of pleuropneumonia, an acute or chronic lung disease of pigs that causes significant morbidity, mortality and economic losses in the worldwide pig industry (Bossé and others 2002, Gottschalk 2012). There are 15 established serovars of the bacterium determined by the composition of the capsular polysaccharide (Gottschalk 2012) with another proposed based on serology alone (Sárközi and others 2015). Determining the serovar allows insights into the epidemiology of A. pleuropneumoniae, for example, to map outbreaks of disease, to identify introductions of serovars not previously detected in countries and to assist in the formulation of bacterin vaccines. Serovar prevalence varies from country to country and with time (Dubreuil and others 2000, Gottschalk 2015). For example, currently serovars 5 and 7 dominate in Canada (Gottschalk and Lacouture 2015), whereas until the 1990s, it was serovar 1 (Gottschalk 2015). In Australia, serovar 15 is highly prevalent (Turni and others 2014) but is rarely reported elsewhere, although it has been recently found in Canada (Gottschalk and Lacouture 2014) and possibly also in Japan (Koyama and others 2007).

The last prevalence study in the UK analysed A. pleuropneumoniae clinical isolates collected in England and Wales between the years 1995 and 2007, with serovar 8 predominant (O'Neill and

Veterinary Record (2016)

Y. Li, BSc, PhD,

W2 1PG, UK

J. T. Bossé, BSc, MSc, PhD, P. R. Langford, BSc, PhD, FRSB, Section of Paediatrics, Imperial College London, St Mary's Campus, London

S. M. Williamson, BVetMed, PhD, MRCVS,

APHA—Bury St Edmunds, Rougham Hill, Bury St Edmunds, Suffolk IP33

D. J. Maskell, BSc MA PhD FMedSci,

A. W. Tucker, BVetMed, PhD, MRCVS.

Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK

doi: 10.1136/vr.103820

B. W. Wren, BSc PhD FRCPath, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK

A. N. Rycroft, BSc, PhD, FRSB,

Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK

E-mail for correspondence: p.langford@imperial.ac.uk

YL and JTB contributed equally.

Provenance: Not commissioned; internally peer reviewed Accepted June 19, 2016

others 2010). In that study, serovar was assigned on the basis of PCR amplification of chromosomal capsule-specific regions; immunological serotyping by slide agglutination having been shown erroneously to overestimate serovars 3 and 6 and underestimate serovar 8 prevalence. Similar underestimation and overestimation were also found in a study of Canadian isolates (Gottschalk 2015). In this study, the authors sought to determine whether the serotype prevalence of A. pleuropneumoniae in England and Wales had changed since 2007 and, in particular, whether new serovars, such as 15, were now present. The isolates evaluated were obtained from clinical cases of diseases in pigs due to A. pleuropneumoniae submitted to the Animal Health and Veterinary Laboratories Agency-Weybridge (AHVLA), now the Animal and Plant Health Agency (APHA), or Royal Veterinary College Diagnostic Laboratories. Isolates were collected between 2008 and 2014. For each year, the number of isolates (in brackets) is as follows: 2008 (N=14); 2009 (N=17); 2010 (N=8); 2011 (N=10); 2012 (N=30); 2013 (N=19)and 2014 (N=15). Bacteria were grown on plates comprising Brain Heart Infusion Agar supplemented with 10 µg/ml nicotinamide adenine dinucleotide. Initially, serotyping was assessed by a multiplex PCR that can distinguish between serovars 1-3, 5-8, 10 and 12 (Bossé and others 2014). The PCR was based on the authors' original serovar 3-6-8 PCR (Zhou and others 2008) but extended to cover all of the serovars reported in England and Wales in the authors' 2010 study (O'Neill and others 2010) and those reported to be prevalent in Europe and North America (Dubreuil and others 2000). A serovar 15-specific PCR (Turni and others 2014) was subsequently used on strains that were untypable by the 1-3, 5-8, 10 and 12 multiplex PCR. Genomic DNA purified using the QIAamp DNA Mini Kit (Qiagen) or single colonies were used as the source of DNA template for PCR reactions as previously described (Bossé and others 2014). In addition to serovar-specific amplicons, the multiplex PCR amplifies a region of the A. pleuropneumoniae-specific apxIVA gene (Schaller and others 2001, Bossé and others 2014). All isolates investigated in this study produced an apxIVA amplicon confirming that they were A. pleuropneumoniae. Comparison of the seroprevalence of A. pleuropneumoniae in England and Wales in this and the authors' previous study is shown in Table 1.

As in the authors' 2010 study, serovar 8 was the most predominant in years 2008–2014 in England and Wales, with a comparatively smaller percentage of serovars 2, 6, 7 and 12. The England and Wales serovar profile contrasts with that found in other European countries. For example, serovar 9/11 predominates in the Czech Republic (Kucerova and others 2005) and serovar 2 in Denmark (Klausen and others 2007), Norway and Sweden (Gottschalk 2012). No serovar 3 isolates were found, possibly reflecting the known low virulence of this serotype (Rosendal and others 1985), and that the A. pleuropneumoniae isolates evaluated were from clinically confirmed cases. Four

TABLE 1: Percentage serovar distribution of *A. pleuropneumoniae* isolates in England and Wales-based studies

Percentage of isolates (number of isolates) in range of years indicated Serovar 1995-2007* 2008-2014† 2 3.4 (13) 6.2 (7) 3 0.5 (2) 6 10.1 (38) 7.1 (8) 7 5.3 (20) 8.0 (9) 8 78.0 (295) 71.7 (81) 3.5 (4) 12 2.7 (10) 3.5 (4)

*O'Neill and others (2010) †Present study NT, non-typable

isolates were non-typable (NT) and subsequent PCR testing established that these were not serovar 15 (Turni and others 2014). Due to their low numbers, the NT isolates were not tested further. The NT isolates could be serovars 4, 9/11, 13, 14, the newly described serovar 16 or variants such that the primers used did not anneal to genomic DNA. Among these, only serovar 9 has been previously reported in Great Britain (McDowell and Ball 1994) or Scotland (Anon 2013).

In summary, the authors' results suggest that serovar 8 *A. pleuropneumoniae* remains the predominant serovar causing clinical disease outbreaks in England and Wales, as in the authors' previous study. Any vaccine to be used in the UK to prevent disease caused by *A. pleuropneumoniae* should have a component targeting serovar 8 isolates and, for near-maximal coverage, additionally serovars 2, 6, 7 and 12.

Acknowledgements

This work was supported by a Longer and Larger (LoLa) grant from the Biotechnology and Biological Sciences Research Council (BBSRC grant numbers BB/G020744/1, BB/G019177/1, BB/G019274/1 and BB/G018553/1) and Zoetis (formerly Pfizer Animal Health) awarded to the Bacterial Respiratory Diseases of Pigs-1 Technology (BRaDP1T) Consortium. The BRaDP1T Consortium comprises Duncan J. Maskell, Alexander W. (Dan) Tucker, Sarah E. Peters, Lucy A. Weinert, Jinhong (Tracy) Wang, Shi-Lu Luan, Roy R. Chaudhuri (University of Cambridge; present address for R. Chaudhuri is Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Western Bank, Sheffield S10 2TN, UK), Andrew N. Rycroft, Gareth A. Maglennon, Jessica Beddow (Royal Veterinary College); Brendan W. Wren, Jon Cuccui, Vanessa S. Terra (London School of Hygiene and Tropical Medicine) and Janine T. Bossé, Yanwen Li and Paul R. Langford (Imperial College London). The DEFRA-funded project "Scanning surveillance for Pig Diseases in England and Wales" (ED1200) funded laboratory and staff costs of obtaining the A. pleuropneumoniae isolates at APHA and the authors are grateful to veterinary and scientific staff at APHA Veterinary Investigation Centres.

Competing interests None declared.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

References

ANON (2013) Animal and Health Veterinary Laboratories Agency Emerging Threats Quarterly Report. Pig Diseases, January–March 2013 (Q1). www. thepigsite.com/articles/4491/ahvla-pig-disease-surveillance-monthly-report-april-2013/. Accessed March 12, 2016

- BOSSÉ, J. T., JANSON, H., SHEEHAN, B. J., BEDDEK, A. J., RYCROFT, A. N., KROLL, J. S. & LANGFORD, P. R. (2002) *Actinobacillus pleuropneumoniae*: pathobiology and pathogenesis of infection. *Microbes and Infection* **4**, 225–235
- BOSSÉ, J. T., LÍ, Y., ANGEN, Ø., WEINERT, L. A., CHAUDHURI, R. R., HOLDEN, M. T., WILLIAMSON, S. M., MASKELL, D. J., TUCKER, A. W., WREN, B. W., RYCROFT, A. N., LANGFORD, P. R. & BRADPIT CONSORTIUM (2014) Multiplex PCR assay for unequivocal differentiation of Actinobacillus pleuropneumoniae serovars 1 to 3, 5 to 8, 10, and 12. Journal of Clinical Microbiology 52, 2380–2385
- DUBREUIL, J. D., JACQUES, M., MITTAL, K. R. & GOTTSCHALK, M. (2000) Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Animal Health Research Reviews 1, 73–93
- GOTTSCHALK, M. (2012) Actinobacillosis. In: Diseases of Swine. 10th edn. Eds. J. J. ZIMMERMAN, A. K. LOCKE, A. RAMIREZ, K. J. SCHWARTZ, G. W. STEVENSON. Ames, Iowa, USA: Wiley-Blackwell, pp 653–659
- GOTTSCHALK, M. (2015) The challenge of detecting herds sub-clinically infected with *Actinobacillus pleuropneumoniae*. *The Veterinary Journal* **206**, 30–38
- GOTTSCHALK, M. & LACOUTURE, S. (2014) Actinobacillus pleuropneumoniae serotypes 3, 6, 8 and 15 isolated from diseased pigs in North America. Veterinary Record 174, 452–452
- GOTTSCHALK, M. & LACOUTURE, S. (2015) Distribution of *Streptococcus suis* (from 2012 to 2014) and *Actinobacillus pleuropneumoniae* (from 2011 to 2014) serotypes isolated from diseased pigs. *Canadian Veterinary Journal* **56**, 1093–1094
- KLAUSEN, J., EKEROTH, L., GRØNDAHL-HANSEN, J. & ANDRESEN, L. O. (2007) An indirect enzyme-linked immunosorbent assay for detection of anti-bodies to Actinobacillus pleuropneumoniae serovar 7 in pig serum. Journal of Veterinary Diagnostic Investigation 19, 244–249
- KOYAMA, T., TO, H. & NAGAI, S. (2007) Isolation of *Actinobacillus pleuropneumoniae* serovar 15-like strain from a field case of porcine pleuropneumonia in Japan. *The Journal of Veterinary Medical Science* **69**, 961–964 KUCEROVA, Z., JAGLIC, Z. & ONDRIASOVA, R. (2005) Serotype distribution of
- KUCEROVA, Z., JAGLIC, Z. & ONDRIASOVA, R. (2005) Serotype distribution of *Actinobacillus pleuropneumoniae* isolated from porcine pleuropneumonia in the Czech Republic during period 2003–2004. *Veterinární Medicina* **50**, 355–360
- Czech Republic during period 2003–2004. Veterinární Medicina **50**, 355–360 MCDOWELL, S. W. & BALL, H. J. (1994) Serotypes of Actinobacillus pleuropneumoniae isolated in the British Isles. Veterinary Record **134**, 522–523
- niae isolated in the British Isles. Veterinary Record 134, 522–523
 O'NEILL, C., JONES, S. C. P., BOSSÉ, J. T., WATSON, C. M., WILLIAMSON, S. M., RYCROFT, A. N., KROLL, J. S., HARTLEY, H. M. & LANGFORD, P. R. (2010) Prevalence of Actinobacillus pleuropneumoniae serovars in England and Wales. Veterinary Record 167, 661–662
- ROSENDAL, S., BOYD, D. A. & GILBRIDE, K. A. (1985) Comparative virulence of porcine *Haemophilus* bacteria. *Canadian Journal of Comparative Medicine* **49**, 68–74
- SÁRKÖZI, R., MAKRAI, L. & FODOR, L. (2015) Identification of a proposed new serovar of *Actinobacillus pleuropneumoniae*: Serovar 16. *Acta Veterinaria Hungarica* **63**, 444–450
- SCHALLER, A., DJORDJEVIC, S. P., EAMENS, G. J., FORBES, W. A., KUHN, R., KUHNERT, P., GOTTSCHALK, M., NICOLET, J. & FREY, J. (2001) Identification and detection of *Actinobacillus pleuropneumoniae* by PCR based on the gene *apxIVA. Veterinary Microbiology* **79**, 47–62
- TÜRNI, C., SINGH, R., SCHEMBRI, M. A. & BLACKALL, P. J. (2014) Evaluation of a multiplex PCR to identify and serotype *Actinobacillus pleuropneumoniae* serovars 1, 5, 7, 12 and 15. *Letters in Applied Microbiology* **59**, 362–369
- ZHOU, L., JONES, S. C. P., ANGEN, Ø., BOSSÉ, J. T., NASH, J. H. E., FREY, J., ZHOU, R., CHEN, H. C., KROLL, J. S., RYCROFT, A. N. & LANGFORD, P. R. (2008) Multiplex PCR that can distinguish between immunologically cross-reactive serovar 3, 6, and 8 Actinobacillus pleuropneumoniae strains. Journal of Clinical Microbiology 46, 800–803

